U.S. Foods Holding Corp: Could This Be the Year’s Best IPO? (USFD)

May 26, 2016, 12:56 pm EDT
U.S. Foods Holding Corp: Could This Be the Year’s Best IPO? (USFD)

US Foods Holding Corp (USFD) may be in the mundane business of food distribution — but investors have nonetheless found excitement with this company. Last night, its initial public offering priced at $23 a share, which was in the upper part of the $21-to-$24 range. Source: AmtrakGuy2010 via Flickr

And so far in today’s trading, the U.S. Foods IPO is up about 8%. The deal is actually the second largest this year, only behind the recent offering for MGM Growth Properties LLC (MGP) .

Yet, the path for the U.S. Foods IPO has not been easy. Back during the height of the buyout boom in 2007, the company went private in a $7 billion deal. But of course, the timing was awful as the U.S. economy would soon plunge into the financial crisis. As a result, U.S. Foods had to take swift actions to restructure the operations. Read 

6 New Stocks to Watch This Week

May 23, 2016, 12:15 pm EDT
6 New Stocks to Watch This Week

By fits and starts, the market for new stocks is getting back into gear. Last week there were four deals that hit the markets. True, the returns were kind of meager — but hey, any activity is a good sign, right? Source: Flickr


The fact is, it will take some time for the market for new stocks to get back to normal levels. Let’s face it, the first few months of this year saw tremendous volatility. Read 

Square Inc: SQ Gets Bent Out of Shape

May 6, 2016, 1:28 pm EDT
Square Inc: SQ Gets Bent Out of Shape

As seen today with Square Inc (SQ) — a provider of online payments systems — the IPO market continues to be treacherous. Wall Street wants to see not just strong growth, but also profitability.

And for SQ stock, this is bad news. On the heels of its second earnings report as a public company, the shares are off a grueling 20% to $10.50.

Keep in mind that the company came public back in November at an offering price of $9. Read 

Biogen Inc (BIIB) to Spin Off Hemophilia Drug Business

May 3, 2016, 12:37 pm EDT

Biogen Inc (BIIB) has announced plans to spin off is hemophilia drug business.

BIIB’s plans would have its hemophilia drug business becoming its own publicly traded company. The objective of the plan is to create two different company’s that can both better focus on their goals and drive value for investors.

The new company being made from Biogen’s hemophilia drug business doesn’t have a name yet. It will have BIIB’s current Pharmaceutical Operations & Technology Executive Vice President John Cox as its CEO. Read 

Koninklijke Philips NV (ADR) IPO: World’s Largest Light Maker Plans Spinoff

May 3, 2016, 11:14 am EDT

Koninklijke Philips NV (ADR) (PHG) has announced plans for an IPO spinoff.

The Philips IPO would have the company selling 25% if its lighting business as it looks to better focus on its medical offerings. It’s the largest lighting company in the world and has the most patents in the industry.

Plans for the Philips IPO that would spinoff its lighting business started two years ago. The company said it was likely the spinoff would occur in its Q1 earnings report released last week. It plans to sell at least a 25% stake of the business on the Euronext Amsterdam as part of the IPO, reports Reuters. Read 

Intellia Therapeutics IPO: The “Biggest Biotech Discovery of the Century”

May 2, 2016, 2:58 pm EDT
Intellia Therapeutics IPO: The “Biggest Biotech Discovery of the Century”

By fits and starts, the market for initial public offerings is getting its footing. Of the four deals on tap this week, all are biotech operators. But among these offerings, there is one that is likely to stand out — Intellia Therapeutics.

Intellia plans to offer 5 million shares at a range of $16 to $18, and the lead underwriters include Credit Suisse Group AG (ADR) (CS), Jefferies and Leerink Partners. The proposed ticker stated in Intellia’s S1 form is NTLA.

The excitement for the IPO centers around Intellia’s Crispr-Cas9 technology, which is a naturally occurring defense mechanism in bacteria that fights against foreign DNA. Dr. Jennifer Doudna, a scientist at Berkeley, sees this as a way to potentially fight cancer and other diseases. Read 

1 2 3 4 5 6 244